TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF THE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET 12
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 PRODUCTS LIFELINE CURVE 21
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.9 DBMR MARKET POSITION GRID 23
2.10 MARKET END USER COVERAGE GRID 24
2.11 VENDOR SHARE ANALYSIS 25
2.12 SECONDARY SOURCES 26
2.13 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 PESTEL ANALYSIS 31
4.2 PORTERS FIVE FORCES 32
5 REGULATORY FRAMEWORK 33
5.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) 33
5.2 REGULATORY FRAMEWORK FOR ECOA 33
5.3 ICH E6 (R2) 33
5.4 FDA GUIDANCE 33
5.5 EMA GUIDELINES 33
5.5.1 ISO 14155 34
5.5.2 PRIVACY REGULATIONS 34
6 MARKET OVERVIEW 35
6.1 DRIVERS 37
6.1.1 GROWING ACCEPTANCE OF ECOA AMONG CLINICAL RESEARCH PROFESSIONALS 37
6.1.2 PARADIGM SHIFT TOWARDS ELECTRONIC DATA CAPTURING FROM PAPER-BASED PROCEDURES 38
6.1.3 GOVERNMENT INITIATIVES ABOUT THE ADOPTION OF ECLINICAL PLATFORMS 39
6.2 RESTRAINTS 39
6.2.1 IMPLEMENTATION OF BRING YOUR OWN DEVICE (BYOD) TECHNOLOGY IN CLINICAL TRIALS 39
6.2.2 LACK OF PROPER HEALTHCARE IT INFRASTRUCTURE IN DEVELOPING COUNTRIES 40
6.3 OPPORTUNITIES 42
6.3.1 GROWING ADOPTION OF CLOUD BASED SERVICES 42
6.3.2 RISING NUMBER OF RESEARCH STUDIES FOCUSING ON CLINICAL OUTCOME ASSESSMENTS 42
6.4 CHALLENGES 43
6.4.1 DIFFICULTIES ASSOCIATED WITH TRAINING OF RESPONDENTS TO FILL ELECTRONIC QUESTIONNAIRES 43
6.4.2 STREAMLINING OF ECOA SERVICES 43
7 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY TYPE 45
7.1 OVERVIEW 46
7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) 49
7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO) 49
7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) 49
7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO) 49
8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY MODALITY 50
8.1 OVERVIEW 51
8.2 SITE-BASED SOLUTIONS 54
8.3 WEB SOLUTIONS 54
8.4 HANDHELD 54
8.4.1 BRING-YOUR-OWN-DEVICE (BYOD) 54
8.4.2 PROVISIONED DEVICES 54
9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY END USER 55
9.1 OVERVIEW 56
9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 59
9.3 PHARMACEUTICAL AND BIOTECHNOLOGY FIRMS 59
9.4 MEDICAL DEVICE COMPANIES 59
9.5 HOSPITALS/HEALTHCARE PROVIDERS 59
9.6 CONSULTING SERVICE COMPANIES 59
9.7 ACADEMIC & RESEARCH INSTITUTES 59
9.8 OTHERS 59
10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY DELIVERY MODE 60
10.1 OVERVIEW 61
10.2 CLOUD-BASED 64
10.3 WEB-HOSTED 64
11 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET BY GEOGRAPHY 65
11.1 EUROPE 65
11.1.1 U.K. 65
11.1.2 GERMANY 65
11.1.3 SPAIN 65
11.1.4 FRANCE 65
11.1.5 ITALY 65
11.1.6 SWITZERLAND 65
11.1.7 NETHERLANDS 65
11.1.8 BELGIUM 66
11.1.9 TURKEY 66
11.1.10 RUSSIA 66
11.1.11 REST OF EUROPE 66
12 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, COMPANY LANDSCAPE 67
12.1 COMPANY SHARE ANALYSIS: EUROPE 67
13 SWOT ANALYSIS 68
14 COMPANY PROFILE 69
14.1 MEDIDATA 69
14.1.1 COMPANY SNAPSHOT 69
14.1.2 REVENUE ANALYSIS 69
14.1.3 COMPANY SHARE ANALYSIS 70
14.1.4 PRODUCT PORTFOLIO 70
14.1.5 RECENT DEVELOPMENTS 70
14.2 CLARIO 71
14.2.1 COMPANY SNAPSHOT 71
14.2.2 COMPANY SHARE ANALYSIS 71
14.2.3 PRODUCT PORTFOLIO 72
14.2.4 RECENT DEVELOPMENT 72
14.3 IBM 73
14.3.1 COMPANY SNAPSHOT 73
14.3.2 REVENUE ANALYSIS 73
14.3.3 COMPANY SHARE ANALYSIS 74
14.3.4 PRODUCT PORTFOLIO 74
14.3.5 RECENT DEVELOPMENT 74
14.4 SIGNANT HEALTH 75
14.4.1 COMPANY SNAPSHOT 75
14.4.2 COMPANY SHARE ANALYSIS 75
14.4.3 PRODUCT PORTFOLIO 76
14.4.4 RECENT DEVELOPMENTS 76
14.5 IQVIA INC, 77
14.5.1 COMPANY SNAPSHOT 77
14.5.2 REVENUE ANALYSIS 77
14.5.3 COMPANY SHARE ANALYSIS 78
14.5.4 PRODUCT PORTFOLIO 78
14.5.5 RECENT DEVELOPMENT 78
14.6 ARISEUROPE 79
14.6.1 COMPANY SNAPSHOT 79
14.6.2 PRODUCT PORTFOLIO 79
14.6.3 RECENT DEVELOPMENTS 80
14.7 CASTOR 81
14.7.1 COMPANY SNAPSHOT 81
14.7.2 PRODUCT PORTFOLIO 81
14.7.3 RECENT DEVELOPMENTS 81
14.8 CLOUDBYZ 82
14.8.1 COMPANY SNAPSHOT 82
14.8.2 PRODUCT PORTFOLIO 82
14.8.3 RECENT DEVELOPMENT 82
14.9 CLINICAL INK. 83
14.9.1 COMPANY SNAPSHOT 83
14.9.2 PRODUCT PORTFOLIO 83
14.9.3 RECENT DEVELOPMENT 83
14.10 EVIDENTIQ 84
14.10.1 COMPANY SNAPSHOT 84
14.10.2 PRODUCT PORTFOLIO 84
14.10.3 RECENT DEVELOPMENT 84
14.11 FOUNTAYN 85
14.11.1 COMPANY SNAPSHOT 85
14.11.2 PRODUCT PORTFOLIO 85
14.11.3 RECENT DEVELOPMENTS 85
14.12 KAYENTIS 86
14.12.1 COMPANY SNAPSHOT 86
14.12.2 PRODUCT PORTFOLIO 86
14.12.3 RECENT DEVELOPMENT 86
14.13 RAYLYTIC GMBH 87
14.13.1 COMPANY SNAPSHOT 87
14.13.2 PRODUCT PORTFOLIO 87
14.13.3 RECENT DEVELOPMENTS 87
14.14 TRANSPERFECT LIFE SCIENCES LIFE SCIENCES 88
14.14.1 COMPANY SNAPSHOT 88
14.14.2 PRODUCT PORTFOLIO 88
14.14.3 RECENT DEVELOPMENT 88
14.15 VITALOGRAPH 89
14.15.1 COMPANY SNAPSHOT 89
14.15.2 PRODUCT PORTFOLIO 89
14.15.3 RECENT DEVELOPMENTS 89
14.16 YPRIME LLC. 90
14.16.1 COMPANY SNAPSHOT 90
14.16.2 PRODUCT PORTFOLIO 90
14.16.3 RECENT DEVELOPMENTS 90
15 QUESTIONNAIRE 91
16 RELATED REPORTS 94

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.